Role of Chest CT in COVID-19
How to cite this article: Malguria N, Yen L, Lin T, Hussein A, Fishman E.K. Role of chest CT in COVID-19. J Clin Imaging Sci 2021;11:30.
In December 2019, a disease attributed to a new severe acute respiratory syndrome coronavirus 2, and named coronavirus disease 2019 (COVID-19), broke out in Wuhan, China and has spread rapidly throughout the world. CT has been advocated in selected indications as a tool toward rapid and early diagnosis. The CT patterns of COVID-19 include ground glass opacities GGO, consolidation, and crazy paving. Additional signs include a “rounded morphology” of lesions, vascular enlargement sign, nodules, and fibrous stripe. Signs of healing and organization include subpleural bands, a reticular pattern, reversed halo sign and traction bronchiectasis. Cavitation and tree in bud signs are absent and pleural effusions are rare. There is a high incidence of pulmonary embolism associated with COVID-19. CT findings in COVID-19 appear to follow a predictable timeline with maximal involvement approximately 6–11 days after symptom onset. The stages of evolution include early stage (days 0–4) with GGO being the predominant abnormality, progressive stage (days 5–8) with increasing crazy paving; and peak stage (days 9–13) with predominance of consolidation and absorption phase (after day 14) with gradual absorption of consolidation with residual GGO and subpleural bands. CT findings in COVID-19 have a high sensitivity and low specificity, determined to be 98% and 25% in a retrospective study of 1014 patients. The low specificity of CT for the diagnosis of COVID-19 pneumonia is due to the overlap of CT findings with other viral pneumonias and other infections, lung involvement in connective tissue disorders, drug reaction, pulmonary edema, and hemorrhage.
In December 2019, a cluster of cases of unexplained pneumonia broke out in Wuhan, China.[1,2] This disease was attributed to a new virus severe acute respiratory syndrome coronavirus 2, and named coronavirus disease 2019 (COVID-19). It has spread rapidly throughout the world and there are currently over 18 million people infected and 689,245 deaths worldwide.
At present, treatment is predominantly supportive and/or experimental[5-8] with the focus of management being rapid diagnosis, isolation of those infected and of asymptomatic contacts. Diagnosis is primarily using real-time polymerase chain reaction (RT-PCR) testing of nasopharyngeal swabs, which have a positive detection rate of 32–63%.[9-11] Recent large-scale studies demonstrate RT-PCR tests turning positive in high risk patients after as many as two initial false negative results.[9,11] CT was used as a means of rapid diagnosis and disease containment in Hubei, China, with the lower mortality than other parts of the world, prompting some authors to advocate widespread use of chest CT as a tool for rapid and early diagnosis and as a measure toward pandemic control;[12,13] while others including the Fleischner society, recommend the use of CT in selected settings.[14,15] In this review, we will discuss the imaging appearances of COVID-19 on CT, review the literature on the diagnostic performance of CT with respect to RT-PCR and the current recommendations for the role CT in COVID-19 pneumonia.
CT IMAGING IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS
Ground glass opacities GGO and consolidations are the most common CT presentation, with a bilateral middle and lower lobe predominance[16-19] and a peripheral distribution (76– 85%).[16,18,20] The disease is usually multifocal, although single lesions may be seen on early imaging, Zhou et al. found single lesions on the initial CT scan in 16.1% of their 62 patients when the scans were performed 2.2 ± 1.8 days after symptom onset and multiple lesions on CT scans performed 6.6 ± 4.4 days after symptom onset.
GGO are areas of hazy increased opacity of the lung parenchyma, with vascular and bronchial margins visible through the opacification [Figure 1], the underlying mechanism being partial displacement of air in the affected alveoli. They are the most common and earliest presentation and have been reported in 34–98% of patients depending on patient population and timing of the CT scan.[12,22-33] Autopsy and pathologic studies have showed the presence of diffuse alveolar damage, perivascular T-cell infiltration and/or hyaline membrane formation,[34-36] features which have been speculated to be the pathological basis of the GGO appearance in COVID-19 pneumonia.
Consolidation [Figure 1] is the second most common pattern seen in patients with COVID-19 and may present in isolation or in combination with GGO.[16,20,25,27,35-40] Consolidation and GGO together represented 83–85% of abnormalities seen by Wang et al. in their series of 90 patients. Consolidation represents more severe disease, compared to GGO. A prospective analysis of 41 patients from Wuhan, China, showed patients admitted to the intensive care unit were more likely to have consolidations that were bilateral and larger (lobular pattern), compared to patients who were not admitted to the intensive care unit who had bilateral GGO and/or smaller (segmental) areas of consolidation. Similarly, Song et al. in their series found consolidations tend to occur more often in older patients compared to younger patients, who have more GGO. Crazypaving refers to the presence of GGO with superimposed interlacing network of lines corresponding to thickening of inter and intralobular septa, similar to the appearance of irregularly shaped paving stones.[41-43] This sign has been reported in CT scans of 5–36% COVID-19 patients [Figures 2 and 3].[24,27,28,44,45] These imaging patterns of peripheral and lower predominant GGO, consolidations, and crazy paving have previously described in diffuse alveolar damage in response to acute lung injury.[46,47]
In addition to the patterns of lung involvement described above, few additional signs have been described. A “rounded morphology” of the consolidation and GGO has been described in 18–33% of patients [Figure 3].[25,39] Vascular thickening, or microvascular enlargement sign consists of enlarged small vessels within the lesions, has been described in 45–80% of patients with COVID-19 pneumonia [Figure 4].[17,41,51] The sign is presumably related to an inflammatory response and release of pro-inflammatory factors.[37,41] Nodules are seen in 2–13% of CT scans in patient with COVID-19 infection,[12,23,49] are usually solid, irregular multifocal, may enlarge or coalesce on follow-up studies or may heal by reduction in density to ground-glass (the melting sugar appearance).[23,52] Fibrous stripes, described by Pan et al. in 17% of patients in their study are linear densities that may appear early and evolve into consolidative areas or appear late in the disease as a sign of healing and organization [Figure 5].[23,37] Other signs of organization and healing by fibrosis include subpleural bands [Figure 6], a reticular pattern [Figure 3], that is, fine linear opacities that by summation produce a net like pattern,[18,45] reversed halo sign [Figure 7] or a ring of peripheral consolidation with central lucency,[27,37,51] and traction bronchiectasis [Figure 8].
Significantly, cavitation and tree in bud signs are absent.[24,42] Pleural effusion appears to be an unusual finding, seen in only one of 121 patients by Bernheim et al. It is relatively rare in early phase disease (<7 days) and appears to be a marker of either advanced[17,24] or severe disease. Other CT markers of disease severity and high viral load described by Zhao et al. include architectural distortion and traction bronchiectasis. Intrathoracic lymph node enlargement is also a rare finding,[27,50] for example, seen by Zhao et al. in only one patient in a series of 101, in a patient with severe clinical disease.
There is a high incidence of acute pulmonary embolism associated with COVID-19 infection,[53,54] reported to be between 22 and 30% among patients who received contrast enhanced CT angiography,[55-57] this risk appears to be higher than that seen in other critically ill patients (1.3%) and emergency room populations (3– 10%).[55,59] On autopsy examination, the lungs of patients who died of COVID-19 demonstrated widespread vascular thrombosis and microangiopathy. Poyiadi et al. observed a reduced risk of pulmonary thromboembolism in COVID-19 patients who had previously been on statin therapy.
CT findings are observed in asymptomatic individuals with positive RT-PCR. GGO appears to be the predominant presentation in asymptomatic patients, seen in 95% of patients, with consolidation seen in the remaining 5%. The distribution is predominantly peripheral, subpleural and lower lobe with a tendency to be confined to one or two lobes (65%). Other signs of COVID-19 pneumonia including reticulation, subpleural curvilinear sign, air bronchogram, and vascular enlargement may be present.
In view of the vast spectrum of findings of CT findings, described in the literature; CT findings maybe categorized as typical, indeterminate, and atypical for COVID-19, with typical features being bilateral peripheral ground glass opacities, with or without consolidation [Figure 1] and crazy paving [Figure 2]; “rounded” morphology lesions [Figure 3] and later in the disease, signs of organizing pneumonia such as reverse halo sign [Figure 7]. Atypical signs on CT, where alternative or additional diseases should be considered include tree in bud nodularity or lung cavitation.
At the time of writing this article, there is limited data to predict outcomes and prognosis based on appearance on imaging. Shi et al. have described imaging appearances in three patients who died of COVID-19 pneumonia. The first patient had underlying chronic lung disease (tuberculosis), and complete opacification of lung parenchyma (white out lung) at presentation. The other two patients demonstrated rapid imaging progression on serial CT scans and one developed a pleural effusion. Colombi et al. quantified the percentage of lung parenchyma not involved by disease on CT (well aerated lung) visually, using segmentation software and also determined the absolute volume of uninvolved lung and they found all three models were superior to clinical parameters alone in predicting intensive care unit admission or death.
TIME COURSE EVOLUTION OF CT FINDINGS
Pan et al. have described the time course of lung changes in 21 patients with mild to moderate COVID-19 pneumonia, and a mean hospitalization period of 17 days, with serial CT scans obtained approximately 4 days apart. They identified four distinct stages of lung involvement (a) early stage; days 0–4 with GGO (75%) being the predominant abnormality, (b) progressive stage; days 5–8 increasing crazy paving (53%); (c) peak stage; days 9–13 with predominance of consolidation (91% of patients); and (d) absorption phase; after day 14 with gradual absorption of consolidation and residual ground glass opacities and subpleural bands. The extent of lung involvement was maximum on day 10 after onset of symptoms. Wang et al. in their prospective longitudinal series of 90 hospitalized patients analyzed for evolution of CT findings similarly showed peak lung involvement on days 6–11. In their series which included severe cases, the extent of lung involvement showed a slow decline after peak involvement. From days 12 to 17 onward they observed a mixed pattern, with architectural distortion and perilobular distribution, suggestive of development of organizing pneumonia.
PERFORMANCE OF CT AS A DIAGNOSTIC MODALITY COMPARED TO RT-PCR
Ai et al. in their retrospective analysis of 1014 patients evaluated during peak endemicity in Wuhan, China (January 6 to February 6 2020) found an initial positive detection rate of 88% (888/1014) for CT and 59% (601/1014) for RT-PCR. Similarly, Fang et al. in their analysis of 51 high risk patients, studied by serial RT-PCR and chest CTs, found an initial detection rate of 98% by CT (95% CI 90–100%), and compared to 71% by RT-PCR (95% CI 56– 83%) (P < 0.001). These low rates of positive detection by RT-PCR using nasopharyngeal swabs are similar to those reported by Wang et al. and may be related to variability between manufacturers, initial low viral load or improper clinical sampling techniques.[52,61-67] On imaging, patients with clinical suspicion of COVID-19 pneumonia who have initial negative RT-PCR that subsequently turns positive on repeat testing tend to have more ground glass and less of consolidation pattern, suggestive of early stage disease and presumably, low viral load.[65,68] In contrast in areas of low COVID-19 prevalence (<10%), Kim et al. in their meta-analysis found that the positive predictive value of RT-PCR (range: 47.3%, –84.3%) was more than 10 times higher than that of CT scans (range: 1.5–8.3%).
The sensitivity and specificity of CT for the detection of COVID-19 pneumonia are hard to estimate precisely, in view of absence of a robust gold standard. Using RT-PCR as a reference standard Ai et al. estimated the sensitivity, specificity, and accuracy of CT in their series of 1014 patients to be 97%, 25%, and 68%, respectively. However, the authors of this study acknowledged that the relatively low positive detection rate of the reference standard likely led to overestimation of sensitivity and underestimation of specificity. Other studies and meta-analysis have similarly demonstrated low specificity for CT in the diagnosis of COVID-19.[69,70] The low specificity of CT for the diagnosis of COVID-19 pneumonia is due to the overlap of CT findings with other viral pneumonias and with other diffuse diseases of the chest such as other infections, lung involvement in connective tissue disorders, drug reaction, pulmonary edema, and hemorrhage.[24,31,71]
Literature describing the performance of radiologists in correctly distinguishing COVID-19 pneumonia from other viral pneumonias or infections is limited. In the study by Bai et al., six out of seven radiologists reached a specificity of 93–100% in correctly distinguishing COVID-19 infection from other viral pneumonias.[16,72] In their study, the most useful discriminating features for COVID-19 pneumonia from other pneumonias were a peripheral distribution (80% vs. 57%, P < 0.001), GGO (91% vs. 68%, P < 0.001), and vascular thickening (58% vs. 22%, P < 0.001). There was been some interest in the role of artificial intelligence (AI) in diagnosing COVID-19 pneumonia with variable results.[73,74] Ito R published a review of 17 studies that used AI with four studies reaching very high sensitivity, specificity, and AUC, in the range of 0.9–0.98, 0.91–0.96, and 0.96–0.99, respectively.
RECOMMENDATIONS FOR THE ROLE OF CT IN COVID-19 PNEUMONIA
Fleischner Society has provided a statement for the role of imaging (chest X-ray and CT scan) in directing patient management in various clinical scenarios. When patients presenting with mild respiratory features of COVID-19 and either suspected or confirmed laboratory diagnosis, imaging is recommended only in the setting of risk factors for disease progression, with common risk factors being age >65 years, cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and immune-compromised status.[15,19,75,76] In patients with clinical presentation of moderate to severe respiratory features of COVID-19 disease (e.g., hypoxemia, moderate to severe dyspnea) imaging is recommended irrespective of laboratory test results. In patients with moderate to severe respiratory features of COVID-19 disease, within an environment of high disease burden, when resources are limited such as medical beds, ventilators, PFE, and no rapid COVID-19 tests, CT can be used to make triage decisions. The society did emphasize that although CT is more sensitive, depending on local expertise and availability, if access to CT is limited, chest X-ray may be the preferred modality; and CT being warranted in circumstances of respiratory worsening. In addition, the Fleischner Society maintains an online repository of characteristic images of proven COVID-19 cases for teaching purposes.
CT scan can help in diagnosis of COVID-19 in the appropriate setting, set a baseline for patients who are at risk for progression, may help to suggest alternate diagnosis and co-morbidities in the high risk patient with COVID-19. In resource limited situations and high disease burden, it is a tool for rapid triage. As the disease and pandemic evolves, there may be further updates in the role of CT in disease management and containment.
Declaration of patient consent
Patient’s consent not required as there are no patients in this study.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
- Available from: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en [Last accessed on 2021 May 19]Pneumonia of Unknown Cause -China. 2020.
- [Google Scholar]
- Available from: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 [Last accessed on 2020 Mar 08]Center for Systems Science and Engineering. 2020.
- [Google Scholar]